Ozanimod not checked

Celgene · BMS-986374 · RPC1063

FollowEvery change as it happens, and a Monday email
Stage
in the US · approved in the EU
Next date
Phase 4 trial completes
Trials
5 active
26 in total · 8 in the EU
Targets
 

What this is

How it works
Sphingosine 1-phosphate Receptor Modulator FDA class
Tested for
Relapsing Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Colitis, Ulcerative
Main trialPhase 4
“The purpose of this study is to assess the effectiveness and safety of ozanimod in Chinese adults with relapsing multiple sclerosis.”In the company’s words, NCT06396039 on ClinicalTrials.gov
Other names
BMS-986374 · RPC1063 · Zeposia · RPC-1063 · RPC 1063

Other drugs for Relapsing Multiple Sclerosis

All 54 drugs for Relapsing Multiple Sclerosis

Coming up3

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials26

TrialPhaseCompletesWhat it tests
Phase 4Active, not recruiting 29 Dec 2028 A Study to Assess the Effectiveness and Safety of Ozanimod in Chinese Adults With Relapsing Multiple Sclerosis
Phase 3Recruiting 11 Apr 2031 Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
Phase 2/3Recruiting 12 Jul 2032 A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
Phase 4Terminated 21 Jan 2025 An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice
Phase 3Completed 27 Mar 2017 Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis
Phase 3Completed 27 Mar 2020 Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis
Phase 3Completed 5 Jan 2023 A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
Phase 3Completed 21 Nov 2023 Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease
Phase 3Terminated 1 Oct 2024 Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease
Phase 3Terminated 3 Oct 2024 A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease
Phase 3Terminated 31 Oct 2024 An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease
Phase 3Completed 19 Dec 2024 An Extension Study of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis
Phase 3Terminated 7 Mar 2025 A Study to Evaluate Efficacy and Long-term Safety of Oral Ozanimod in Chinese Participants With Moderately to Severely Active Ulcerative Colitis (UC)
Phase 3Terminated 15 May 2025 Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063)
Phase 3Completed 30 Sep 2025 To Evaluate Efficacy and Long-term Safety of Ozanimod in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis
Phase 2/3Completed 13 Apr 2014 Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients
Phase 2/3Terminated 13 Sep 2024 A Study to Evaluate the Efficacy, Safety, and Drug Levels of Oral Ozanimod in Pediatric Participants With Moderately to Severely Active Crohn's Disease With an Inadequate Response to Conventional Therapy
Phase 2Completed 10 Mar 2015 Efficacy and Safety Study of Ozanimod in Ulcerative Colitis
Phase 2Completed 12 Sep 2019 Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease
Phase 1Completed 26 Sep 2020 A Study to Evaluate the Pharmacokinetics of Single Oral Doses of Ozanimod in Healthy Adult Chinese Subjects
Phase 1Completed 19 May 2021 A Study to Evaluate the Relative Bioavailability of a Pediatric Granule Formulation of Ozanimod in Healthy Adult Subjects
Phase 1Completed 17 Sep 2021 Taste Assessment of Ozanimod
Phase 1Completed 6 Apr 2022 A Phase 1, Multicenter, Open-Label Study to Evaluate the Effect of Mild or Moderate Hepatic Impairment on the Multiple-Dose Pharmacokinetics of Ozanimod
Phase 1Completed 26 Feb 2023 Study to Evaluate the Pressor Effect of Oral Tyramine During Ozanimod Treatment in Healthy Adult Participants
Phase 4Authorised not given Effects of ozanimod on myelin dynamics and neurodegeneration in patients with relapsingremitting multiple sclerosis: correlation with disease activity, cognition, fatigue,depression and quality of life
Phase 4Authorised not given Effect of ozanimod on meningeal inflammation and glial activation in Multiple Sclerosis: one year phase 4 experimental study PROTOCOL CODE: OZA22 / IM047 - 048
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Ozanimod

Following is part of Solo: you see every change to Ozanimod the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in